Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

被引:135
|
作者
Nolan, D
Upton, R
McKinnon, E
John, M
James, I
Adler, B
Roff, C
Vasikaran, S
Mallal, S [1 ]
机构
[1] Royal Perth Hosp, Dept Clin Immunol, Ctr Clin Immunol & Biomed Stat, Perth, WA 6000, Australia
[2] Murdoch Univ, Murdoch, WA 6150, Australia
[3] Royal Perth Hosp, Dept Nucl Med, Perth, WA, Australia
[4] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA, Australia
关键词
bone mineral density; HAART; indinavir; lipodystrophy syndrome; nelfinavir; protease inhibitors; osteopenia; osteoporosis; subcutaneous fat wasting;
D O I
10.1097/00002030-200107060-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and objectives: To determine the factors contributing to changes in bone mineral density (BMD) over time in HIV-infected patients receiving highly active antiretroviral therapy (HAART). Methods: Analyses of lumbar spine BMD in 183 male Caucasian participants in the Western Australian HIV Cohort study, comprising a longitudinal analysis of data from 54 patients on stable HAART regimens, and a cross-sectional analysis comparing data from 131 protease inhibitor (PI)-treated patients and 52 PI-naive (including 28 antiretroviral treatment-naive) patients. Results: Average lumbar spine BMD remained stable or increased over the time frame considered. Although there was no evidence of a change of average BMD over time in patients receiving nelfinavir (P = 0.92), there was evidence of increasing bone density in the indinavir group (average increase, 0.31 z-score per year; P < 0.001). Lower initial z-scores in the longitudinal analysis were significantly associated with lower pre-HAART BMI (P = 0.003), consistent with results of the cross-sectional analysis in which lowest BMI prior to initial dual X-ray absorptiometry scan was associated with decreased BMD (P = 0.02, overall group). Although PI therapy was also associated with decreased BMD in a univariate analysis of the cross-sectional data (P = 0.04), this effect was abrogated in a multiple linear regression analysis (P = 0.11) with lowest BMI remaining significant (P = 0.04). Conclusions: We found no evidence, overall, of accelerated bone loss in patients treated with nelfinavir- or indinavir-containing HAART regimens, and propose that indinavir therapy may be associated with an increase in bone mineral density over time. Pre-HAART BMI was an independent and powerful determinant of an individual's initial z-score in the longitudinal analysis, and adjustment for this effect in a cross-sectional analysis abrogated the association between P1 therapy and decreased lumbar spine z-score. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1275 / 1280
页数:6
相关论文
共 50 条
  • [31] Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals
    Grant, Philip M.
    Kitch, Douglas
    McComsey, Grace A.
    Collier, Ann C.
    Koletar, Susan L.
    Erlandson, Kristine M.
    Yin, Michael T.
    Bartali, Benedetta
    Ha, Belinda
    Melbourne, Kathy
    Brown, Todd T.
    JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (04): : 607 - 611
  • [32] Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy
    Bolland, Mark J.
    Grey, Andrew B.
    Horne, Anne M.
    Briggs, Simon E.
    Thomas, Mark G.
    Ellis-Pegler, Rod B.
    Woodhouse, Andrew F.
    Gamble, Greg D.
    Reid, Ian R.
    CLINICAL ENDOCRINOLOGY, 2006, 65 (02) : 191 - 197
  • [33] Alterations in bone mineral metabolism in Brazilian HIV-infected patients
    Santos, ACS
    Crisostomo, LML
    Olavarria, V
    Brites, C
    Galvao-Castro, B
    AIDS, 2003, 17 (10) : 1578 - +
  • [34] High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy
    Goujard, U
    Legrand, M
    Panhard, X
    Diquet, B
    Duval, X
    Peytavin, G
    Vincent, I
    Katlama, C
    Leport, C
    Bonnet, B
    Salmon-Céron, D
    Mentré, F
    Taburet, AM
    CLINICAL PHARMACOKINETICS, 2005, 44 (12) : 1267 - 1278
  • [35] Reduced bone mineral density among HIV-infected patients in Taiwan: Prevalence and associated factors
    Tsai, Mao-Song
    Hung, Chien-Ching
    Liu, Wen-Chun
    Chen, Kuan-Lin
    Chen, Mao-Yuan
    Hsieh, Szu-Min
    Sheng, Wang-Huei
    Sun, Hsin-Yun
    Shih, Tiffany T. F.
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2014, 47 (02) : 109 - 115
  • [36] Reduced Quantitative Ultrasound Bone Mineral Density in HIV-Infected Patients on Antiretroviral Therapy in Senegal
    Cournil, Amandine
    Eymard-Duvernay, Sabrina
    Diouf, Assane
    Moquet, Claire
    Coutherut, Julie
    Gueye, Ndeye Fatou Ngom
    Cames, Cecile
    Taverne, Bernard
    Bork, Kirsten
    Sow, Papa Salif
    Delaporte, Eric
    PLOS ONE, 2012, 7 (02):
  • [37] Association of lean mass with bone mineral density in young, recently diagnosed HIV-infected patients
    Gallego Galiana, J.
    Vivancos, M.
    Gioia, F.
    Sobrino, C.
    Perez-Elias, M.
    Moreno, A.
    Moreno, S.
    Vazquez, M.
    Casado, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [38] Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients
    J. L. Casado
    S. Bañon
    R. Andrés
    M. J. Perez-Elías
    A. Moreno
    S. Moreno
    Osteoporosis International, 2014, 25 : 1071 - 1079
  • [39] Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
    Makras, Polyzois
    Petrikkos, Panagiotis
    Anastasilakis, Athanasios D.
    Kolynou, Artemis
    Katsarou, Angeliki
    Tsachouridou, Olga
    Metallidis, Symeon
    Yavropoulou, Maria P.
    BONE REPORTS, 2021, 15
  • [40] Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients
    Casado, J. L.
    Banon, S.
    Andres, R.
    Perez-Elias, M. J.
    Moreno, A.
    Moreno, S.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 (03) : 1071 - 1079